Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (February 2017)

19 slides from Sorrento Therapeutics's investor presentation, February 2017

  1. Slide 1: Corporate Presentation

    Corporate Presentation February 2017

  2. Slide 2: Disclaimer

    Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in th

  3. Slide 3: Sorrento Therapeutics Overview

    Sorrento Therapeutics Overview › Antibody-centric, clinical stage biopharmaceutical company founded in 2006 Partners Subs/JVs › Goal: to deliver clinically meaningful therapies to patients and leverage on proprietary targeted and cellular therapy platforms › Focus: transform cancer into a treatable

  4. Slide 4: Core Technologies and Programs Under Development

    Core Technologies and Programs Under Development CAR-based › Autologous and allogeneic CAR-T and CAR.NK therapies › Targets include CD38 for Multiple Myeloma, CD123 for Acute Myeloid Leukemia, CEA, and PSMA Immunotherapies › IND filings expected in 2017 Oncolytic Virus › Binding term sheet to acquir

  5. Slide 5: Corporate Structure

    Corporate Structure © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 5

  6. Slide 6: Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma (MM)

    Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma (MM) MM Overview: › ACS estimated 30,330 new multiple myeloma cases in 2016 › Malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure Anti-CD38 CAR-T Cells Selectively Lyse CD38 High E

  7. Slide 7: Seprehvir - Leading Next-Generation HSV-1 based Oncolytic Virus Immunotherapy

    Seprehvir® - Leading Next-Generation HSV-1 based Oncolytic Virus Immunotherapy  Seprehvir® (HSV1716) is a Phase II-ready HSV-1 based immuno-oncolytic therapy with over 100 patients treated to date and no adverse events  Designed with the ability to specifically target and destroy tumor cells while

  8. Slide 8: Seprehvir - Safe in Over 100 patients and Three Delivery Routes

    Seprehvir® - Safe in Over 100 patients and Three Delivery Routes By Indication By Delivery Route Systemic 6% Non-CNS Loco-regional 15% 12% MPM HGG 12% 48% Melanoma Intratumoral 5% HNSCC 82% 20%  101 patients treated with Seprehvir® in the U.S. and Europe (as of December 2016)  Well tolerated, no t

  9. Slide 9: Antibody Therapeutics: G-MAB Library

    Antibody Therapeutics: G-MAB Library Difficult Targets High Value Oncology Targets G Protein-Coupled Receptors Small Peptides & Tumor Neo-epitopes PD1, PD-L1, CD123, TIM3, CD47 (GPCRs) F L S Y G N A G AIP-2 One of the Largest Fully Human Highly Successful Screening Hit Rate Antibody Libraries 100+ c

  10. Slide 10: Antibody Therapeutics: Pipeline

    Antibody Therapeutics: Pipeline Lead Candidates in Development › STI-A1014 (PD-L1 mAb) o IND filing in 2017 in CN › STI-A1110 (PD-1 mAb) with Servier o IND-enabling studies › STI-A1015 (PD-L1 mAb) with Yuhan o IND-enabling studies in KR o US clinical trial initiation expected in 1H18 › c-MET ADC o I

  11. Slide 11: Antibody Therapeutics: Anti-PD-1 Transaction with Servier

    Antibody Therapeutics: Anti-PD-1 Transaction with Servier › On July 6, 2016 Sorrento announced a license and collaboration agreement with Laboratoires Servier for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 mAb STI-A1110 o STI

  12. Slide 12: Antibody-Drug Conjugates (ADCs): Concortis Biotherapeutics

    Antibody-Drug Conjugates (ADCs): Concortis Biotherapeutics Next-Generation Antibody-Drug Conjugates › Cytotoxic drugs conjugated to antibodies via chemical linkers › Site-specific conjugation methods to provide homogenous products o K-Lock™ and C-Lock™ › Proprietary toxins: tubulin-binding, DNA alky

  13. Slide 13: LA Cell: iTAb (Intracellular Targeting Antibody) Platform

    LA Cell: iTAb (Intracellular Targeting Antibody) Platform Current mAb/protein drugs target extracellular proteins, either New Class of Drugs for Unmet secreted or membrane bound Medical Needs 2015 sales < 10% potential $169 billion druggable space LA Cell’s proprietary iTAb platform enables the abil

  14. Slide 14: LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company

    LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company Program Stage Activities In-Vivo Efficacy Studies STAT3 Lead Optimization Developability Assessment MYC Lead Discovery Functionality Evaluation FOXP3 Lead Discovery Antibody Modification KRAS Lead Discovery Antibody Modifi

  15. Slide 15: Sorrento Biologics: Biosimilars and Biobetters

    Sorrento Biologics: Biosimilars and Biobetters Pipeline Overview › Exclusive licensing agreement with Mabtech Limited to develop and commercialize biosimilar antibodies › 4 antibodies to-date, targeting ~$9B global market: Sorrento Global Sales Generic Target Brand Antibody (2015 WW) STI-001 Cetuxim

  16. Slide 16: Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs

    Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs RTX SP-102 ZTlido™ (resiniferatoxin) (lidocaine patch 1.8%) • Non-opiate epidural steroid • Non-opioid-based ultrapotent injectable • Anhydrous, single-layer lidocaine Asset Overview TRPV1 agonist neurotoxin injectable patch bas

  17. Slide 17: Global Partners: Immuno-Oncology, Cellular Therapy, ADC

    Global Partners: Immuno-Oncology, Cellular Therapy, ADC Partner Asset Type Partner Background Partnership Details • License and collaboration agreement for the development, manufacture and • Servier is the largest non-listed pharmaceutical Laboratoires Servier Immuno-Oncology company in France comme

  18. Slide 18: 2016 Strategic Accomplishments

    2016 Strategic Accomplishments • Servier PD-1 mAb license validates core G-MAB technology with potential development and Core Technology Validation commercial milestones totaling about $1 billion • Pain management franchise built out and moving forward with internal investments and acquisitions (SCI

  19. Slide 19: Contact Us

    Contact Us (858) 210-3700 9380 Judicial Drive, San Diego, CA 92121 [email protected] © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 19

Sorrento Therapeutics — Investor Presentation (February 2017) on 6ix